Have a personal or library account? Click to login
Description of Methodology for Testing the Synergistic and Additive Effects of Antibiotics in Vitro Cover

Description of Methodology for Testing the Synergistic and Additive Effects of Antibiotics in Vitro

Open Access
|Jan 2025

References

  1. Bellio P., Fagnani L., Nazzicone L., Celenza G.: New and simplified method for drug combination studies by checkerboard assay. MethodsX, 8, 101543 (2021)
  2. Brennan-Krohn T., Kirby J.E.: When One Drug Is Not Enough: Context, Methodology, and Future Prospects in Antibacterial Synergy Testing. Clin. Lab. Med. 39, 345–358 (2019a)
  3. Brennan-Krohn T., Kirby J.E.: Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method. J.Vis. Exp. 146, 10.3791/58636 (2019b)
  4. Brennan-Krohn T., Truelson K.A., Smith K.P., Kirby J.E.: Screening for synergistic activity of antimicrobial combinations against carbapenem-resistant Enterobacteriaceae using inkjet printer-based technology. J. Antimicrob. Chemother. 72, 2775–2781 (2017)
  5. Doern C.D.: When does 2 plus 2 equal 5? A review of antimicrobial synergy testing. J. Clin. Microbiol. 52, 4124–8 (2014)
  6. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Break point_tables/v_14.0_Breakpoint_Tables.pdf EUCAST. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 14.0, valid from 2024-01-01. 19.05.2024
  7. https://atlas.ecdc.europa.eu/public/index.aspx. European Centre for Disease Prevention and Control. Surveillance Atlas of Infectious Diseases, 13.04.2024
  8. Fatsis-Kavalopoulos N., Roemhild R., Tang P.-C., Kreuger J., Andersson D.I.: CombiANT: Antibiotic interaction testing made easy, PLOS Biol. 18, e3000856 (2020)
  9. Gaudereto J.J., Neto L.V.P., Leite G.C., Espinoza E.P.S., Martins R.C.R., Prado G.V.B., Rossi F., Guimarães T., Levin A.S., Costa S.F.: Comparison of methods for the detection of in vitro synergy in multidrug-resistant gram-negative bacteria. BMC Microbiol. 20, 97 (2020)
  10. Garbusińska A., Szliszka E.: Aktywność leków przeciwdrobno-ustrojowych zastosowanych w kombinacjach wobec pałeczek Gram-ujemnych w badaniach in vitro. Post. N. Med., XXX(08), 427–433 (2017)
  11. Guzek A.: Metodologia oznaczania synergizmu między antybio-tykami z zastosowaniem pasków z gradientem stężeń antybio-tyków w warunkach in vitro. Forum Zakażeń, 14, 19–24 (2023)
  12. Karakonstantis S., Ioannou P., Kofteridis D.D.: In search for a synergistic combination against pandrug-resistant A. baumannii; methodological considerations. Infection, 50, 569–581 (2022)
  13. Laishram S., Pragasam A.K., Bakthavatchalam Y.D., Veerara-ghavan B.: An update on technical, interpretative and clinical relevance of antimicrobial synergy testing methodologies. Indian J. Med. Microbiol. 35, 445–468 (2017)
  14. Marie M.A.M., Krishnappa L.G., Alzahrani A.J., Mubaraki M.A., Alyousef A.A.: A prospective evaluation of synergistic effect of sulbactam and tazobactam combination with meropenem or colistin against multidrug resistant Acinetobacter baumannii. Bosn. J. Basic Med. Sci. 15, 24–29 (2015)
  15. Nasomsong W., Nulsopapon P., Changpradub D., Pungcharoen-kijkul S., Hanyanunt P., Chatreewattanakul T., Santimaleeworagun W.: Optimizing Doses of Ceftolozane/Tazobactam as Monotherapy or in Combination with Amikacin to Treat Carbape-nem-Resistant Pseudomonas aeruginosa. Antibiotics (Basel), 11, 517 (2022)
  16. Okoliegbe I.N., Hijazi K., Cooper K., Ironside C., Gould I.M.: Antimicrobial Synergy Testing: Comparing the Tobramycin and Ceftazidime Gradient Diffusion Methodology Used in Assessing Synergy in Cystic Fibrosis-Derived Multidrug-Resistant Pseudomonas aeruginosa. Antibiotics (Basel), 10, 967 (2021)
  17. Papoutsaki V., Galani I., Papadimitriou E., Karantani I., Karaiskos I., Giamarellou H.: Evaluation of in vitro methods for testing tigecycline combinations against carbapenemase-producing Klebsiella pneumoniae isolates. J. Global Antimicrob. Resist. 20, 98–104 (2020)
  18. https://pharmaceutical-journal.com/article/news/only-12-new-antibiotics-entered-the-market-in-five-years-who-warns-in-review Sayburn A.: Only 12 new antibiotics entered the market in five years, WHO warns in review. The Pharmaceutical Journal, 310 (2023), 04.12.2024
  19. Sreenivasan P., Sharma B., Kaur S., Rana S., Biswal M., Ray P., Angrup A.: In-vitro susceptibility testing methods for the combination of ceftazidime-avibactam with aztreonam in metallobeta-lactamase producing organisms: Role of combination drugs in antibiotic resistance era. J. Antibiot. (Tokyo), 75, 454–462 (2022)
  20. Tang P.-C., Sánchez-Hevia D.L., Westhoff S., Fatsis-Kavalopoulos N., Andersson D.I.: Within-species variability of antibiotic interactions in Gram-negative bacteria. mBio, 15, e0019624 (2024)
  21. https://iris.who.int/bitstream/handle/10665/354545/9789240047655-eng.pdf?sequence=1. WHO. World Health Organization: 2021 Antibacterial agents in clinical and preclinical development: an overview and analysis, 13.04.2024
  22. https://antybiotyki.edu.pl/wp-content/uploads/Biuletyn/Biuletyn-Informacyjny-2_2022.pdf Żabicka D., Grzegorczyk M.: Oporność na antybiotyki w Polsce i Europie w 2021 roku-dane sieci EARS-Net. Oporność na antybiotyki. Biuletyn informacyjny, 2 (2022), 19.05.2024
DOI: https://doi.org/10.2478/am-2024-0017 | Journal eISSN: 2545-3149 | Journal ISSN: 0079-4252
Language: English, Polish
Page range: 199 - 222
Submitted on: Aug 1, 2024
|
Accepted on: Nov 1, 2024
|
Published on: Jan 29, 2025
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2025 Paweł Z. Kmiecikowski, Aniela Gabriel, Dagmara Depka, Tomasz Bogiel, published by Polish Society of Microbiologists
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.